Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133418 | 0.89 | L3MBTL3 (0.51) | TDP2L3MBTL3L3MBTL1FAAHMCHR1 | |
| SCHEMBL4132414 | 0.89 | HRH3 (0.45) | HRH3L3MBTL3L3MBTL1FAAH | |
| SCHEMBL4140118 | 0.88 | TDP2 (0.45) | HRH3TDP2L3MBTL3L3MBTL1FAAH | |
| SCHEMBL4144270 | 0.88 | TDP2 (0.45) | HRH3TDP2L3MBTL3L3MBTL1FAAH | |
| SCHEMBL4140115 | 0.88 | TDP2 (0.45) | HRH3TDP2L3MBTL3L3MBTL1FAAH | |
| SCHEMBL4136371 | 0.88 | HRH3 (0.52) | HRH3L3MBTL3L3MBTL1MCHR1 | |
| SCHEMBL4136377 | 0.88 | HRH3 (0.52) | HRH3L3MBTL3L3MBTL1MCHR1 | |
| SCHEMBL4136321 | 0.86 | TDP2 (0.45) | HRH3TDP2L3MBTL3L3MBTL1FAAH | |
| SCHEMBL4132295 | 0.86 | USP30 (0.41) | HRH3L3MBTL3L3MBTL1FAAHMCHR1 | |
| SCHEMBL4135783 | 0.85 | GRIA2 (0.52) | HRH3FAAHRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885PARP10 3228/4885PARP11 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.